Back to top
more

iShares Biotechnology ETF: (IBB)

(Delayed Data from NASDAQ) As of Oct 20, 2025 03:45 PM ET

$156.30 USD

156.3
1,922,435

+2.11 (1.37%)

Volume: 1,922,435

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

After-Market: $156.51 +0.21 (0.13 %) 4:52 PM ET

Zacks News

Sweta Jaiswal, FRM headshot

Get Your Portfolio Christmas-Ready With These ETFs

Here we highlight some ETFs that can help investors make the most of the favorable investing opportunities amid the coronavirus crisis.

Kevin Cook headshot

Moderna Vaccine: The Power of mRNA Technology

Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine

Sweta Jaiswal, FRM headshot

ETF Sectors to Bet on Positive Vaccine News

The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.

Sweta Jaiswal, FRM headshot

Moderna ETFs to Shine on Vaccine News as Outbreak Worsens

Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.

Sweta Jaiswal, FRM headshot

Here's Why Healthcare ETFs Are Rallying Post Elections

Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to These Q3 Earnings Release?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.

Sweta Jaiswal, FRM headshot

Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain

Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Shine on Coronavirus Antibodies Progress

With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.

Sweta Jaiswal, FRM headshot

5 ETFs That Make Attractive Investment Choices in Q4

Here we discuss ETFs that can be a good addition for enhanced portfolio returns in the fourth quarter of 2020.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain on Trump's COVID-19 Treatment Protocol

The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.

Sweta Jaiswal, FRM headshot

Top-Performing Biotech ETFs Amid the Coronavirus Crisis

The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies

Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.

Sweta Jaiswal, FRM headshot

ETFs to Gain as AstraZeneca Resumes Coronavirus Vaccine Trial

AstraZeneca's resumption of the late-stage trials can revive investors optimism surrounding the coronavirus vaccine development.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?

Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.

Sweta Jaiswal, FRM headshot

ETF Areas to Consider This Cursed September Amid Coronavirus

Let's look at some ETF areas one can consider investing in for a smooth sail amid the turbulences September can usher in.

Sweta Jaiswal, FRM headshot

Will Novavax ETFs Gain on Coronavirus Vaccine Progress?

Investors are closely tracking the progress in the coronavirus vaccine development amid the coronavirus outbreak.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress

AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.

Sweta Jaiswal, FRM headshot

Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data

Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.

Sweta Jaiswal, FRM headshot

Beat the Fed Minutes Blues With These ETF Areas

Let's look at some ETF areas that might continue being prudent investing options at a time when the Fed seems worried about the impact of the coronavirus outbreak on the U.S. economy.

Sweta Jaiswal, FRM headshot

Moderna ETFs to Shine on U.S. Contracts for Coronavirus Vaccine

Moderna has inked a $1.5-billion coronavirus vaccine supply agreement with the U.S. government.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to Q2 Earnings Release?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q2 earnings releases amid the coronavirus crisis.